联合呋塞米应激试验与CCL14预测术后患者肾替代治疗指征的发生
该单中心、前瞻性、观察性研究在德国明斯特大学医院纳入208例危重术后中度AKI(KDIGO 2期)且伴进展风险因素(使用血管活性药和/或机械通气)并接受呋塞米应激试验(FST)的患者,检测CCL14、NGAL、DPP3等生物标志物。主要终点为出现至少一项预设肾替代治疗(RRT)指征,98例(47%)达到,FST阴性队列中达82%。入选时FST阴性联合高尿CCL14预测主要终点的AUC为0.87(95%CI 0.82-0.92),显著高于单用FST(AUC 0.79,95%CI 0.74-0.85)或单用CCL14(AUC 0.83,95%CI 0.77-0.89),P<0.001。作者认为联合FST与CCL14可预测RRT指征的发生。
要点
- 208例术后KDIGO 2期AKI且使用血管活性药和/或机械通气的重症患者中,98例(47%)出现至少一项预设RRT指征。
- FST阴性(FST后2小时尿量<200 mL)患者中82%达到主要终点。
- FST阴性联合高尿CCL14预测RRT指征的AUC为0.87(95%CI 0.82-0.92),高于单用FST(AUC 0.79,95%CI 0.74-0.85)和单用CCL14(AUC 0.83,95%CI 0.77-0.89),P<0.001。
- 其他生物标志物(NGAL、DPP3)的AUC更低。
- 预设RRT指征包括高钾血症(≥6 mmol/L)、利尿剂抵抗的高容量、高尿素血症(≥150 mg/dL)、严重代谢性酸中毒(pH≤7.15)、少尿(尿量<200 mL/12小时)或无尿。
适用人群与场景
- 危重、术后、中度AKI(KDIGO 2期)且伴进一步进展风险因素(使用血管活性药和/或机械通气)并接受FST的患者。
- 单中心、前瞻性、观察性研究,地点为德国明斯特大学医院。
诊断标准与关键阈值
- AKI诊断标准:KDIGO 2期。
- FST阴性定义:FST后2小时内尿量<200 mL。
- 主要终点为出现至少一项预设RRT指征:高钾血症(≥6 mmol/L)、利尿剂抵抗的高容量、高尿素血清水平(≥150 mg/dL)、严重代谢性酸中毒(pH≤7.15)、少尿(尿量<200 mL/12小时)或无尿。
研究设计与关键结果
- 研究类型:单中心、前瞻性、观察性研究;208例患者纳入主要分析,其中108例FST阴性。
- 主要终点:98例(47%)达到至少一项预设RRT指征,FST阴性队列中82%达到。
- 入选时FST阴性联合高尿CCL14预测主要终点的AUC为0.87(95%CI 0.82-0.92),显著高于单用FST(AUC 0.79,95%CI 0.74-0.85)或单用CCL14(AUC 0.83,95%CI 0.77-0.89),P<0.001。
- 其他生物标志物(NGAL、DPP3)的AUC更低。
证据类型、等级与局限
- 证据类型:单中心、前瞻性、观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在术后KDIGO 2期AKI且使用血管活性药和/或机械通气的重症患者中,联合FST与尿CCL14可能有助于预测后续RRT指征的发生。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Optimal timing of renal replacement therapy (RRT) initiation in severe acute kidney injury (AKI) remains controversial. Initiation of treatment early in the course of AKI may lead to some patients undergoing unnecessary RRT, whereas delayed treatment is associated with increased mortality. This study aims to investigate whether the combination of the furosemide stress test (FST) and AKI-associated biomarkers can predict the development of indications for RRT.
DESIGN: Single-center, prospective, observational study.
SETTING: University Hospital of Muenster, Germany.
PATIENTS: Critically ill, postoperative patients with moderate AKI (Kidney Disease: Improving Global Outcomes stage 2) and risk factors for further progression (vasopressors and/or mechanical ventilation) receiving an FST.
INTERVENTIONS: Sample collection and measurement of different biomarkers (chemokine [C-C motif] ligand 14 [CCL14], neutrophil gelatinase-associated lipocalin, dipeptidyl peptidase 3).
MEASUREMENT AND MAIN RESULTS: The primary endpoint was the development of greater than or equal to one predefined RRT indications (hyperkalemia [≥ 6 mmol/L], diuretic-resistant hypervolemia, high urea serum levels [≥ 150 mg/dL], severe metabolic acidosis [pH ≤ 7.15], oliguria [urinary output < 200 mL/12 hr], or anuria). Two hundred eight patients were available for the primary analysis with 108 having a negative FST (urine output < 200 mL in 2 hr following FST). Ninety-eight patients (47%) met the primary endpoint, 82% in the FST negative cohort. At the time of inclusion, the combination of a negative FST test and high urinary CCL14 levels had a significantly higher predictive value for the primary endpoint with an area under the receiver operating characteristic curve (AUC) of 0.87 (95% CI, 0.82-0.92) compared with FST or CCL14 alone (AUC, 0.79; 95% CI, 0.74-0.85 and AUC, 0.83; 95% CI, 0.77-0.89; p < 0.001, respectively). Other biomarkers showed lower AUCs.
CONCLUSIONS: The combination of the FST with the renal biomarker CCL14 predicts the development of indications for RRT.
参考来源
- Meersch M, Weiss R, Gerss J, et al. Predicting the Development of Renal Replacement Therapy Indications by Combining the Furosemide Stress Test and Chemokine (C-C Motif) Ligand 14 in a Cohort of Postsurgical Patients. Crit Care Med. 2023. PMID: 36988335. doi:10.1097/CCM.0000000000005849
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。